Mayo Clinic researchers have validated a threshold designed to help determine if an antidepressant used for depression is working, but not well enough to be continued.
A collaborative team of scientists led by Mayo Clinic's Center for Individualized Medicine has discovered 15 additional genetic mutations in the KCNK9 gene that cause a neurodevelopmental syndrome. Symptoms of the disorder range from speech and motor impairment to behavioral abnormalities, intellectual disability and distinctive facial features.
https://vimeo.com/717112504
The American Association for Cancer Research today released its Cancer Disparities Progress Report 2022. The publication aims to raise awareness of the enormous toll [...]
Vulnerability to heart disease can be projected before symptoms occur, Mayo Clinic discovered in preclinical research. This proof-of-concept study revealed that heart muscle [...]
In a new study published in Nature Microbiology, researchers demonstrated the power of integrating the microbiome and host gene expression data to provide [...]
Mark Pearce, 61, was facing a possible limb amputation, even death, when a multidrug-resistant bacterial infection within his prosthetic hip replacement device started raging in his bloodstream. With his fever soaring to more than 105 degrees, Mark was taken by ambulance, that day in spring of 2020, to Mayo Clinic Hospital in Rochester, Minnesota.
Iftikhar Kullo, MD., has been invited to serve on the National Advisory Council on Human Genome Research (NACHGR) of the National Institutes of [...]
Researchers at Mayo Clinic's Center for Individualized Medicine have devised an immunotherapy technique that combines chimeric antigen receptor-T cell therapy, or CAR-T cell therapy, with a cancer-killing virus to more effectively target and treat solid cancer tumors.